Clinical Trials Logo
  1. Home
  2. Follicular Thyroid Cancer
  3. NCT06437873

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Follicular Thyroid Cancer Clinical Trial

Official title:
Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 Follicular Thyroid Carcinoma:A Retrospective Propensity Score-Matched Study

Clinical Trial Summary

This study aims to thoroughly examine survival disparities in patients with T3 or T4 stage follicular thyroid carcinoma (FTC) as classified by the AJCC staging system. It compares outcomes between those who underwent total thyroidectomy (TT) and those who did not, and assesses the influence of radioactive iodine therapy (RAIT) on the survival of patients without TT. Utilizing the SEER database, a retrospective study identified patients diagnosed with T3 or T4 FTC, categorizing them into two cohorts: those treated with TT and those who were not (No-TT). The No-TT group was further analyzed to determine the impact of RAIT on patient survival. Propensity score matching (PSM) was applied to adjust for confounding variables. Survival analysis, including Kaplan-Meier survival curves and Landmark analysis, was conducted to evaluate the effects of surgical intervention and RAIT on overall survival (OS) and cancer-specific survival (CSS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06437873
Study type Observational
Source Dezhou Hospital Qilu Hospital of Shandong University
Contact
Status Completed
Phase
Start date January 1, 2000
Completion date May 25, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03639662 - Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer N/A
Completed NCT01441154 - Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Active, not recruiting NCT01723202 - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Recruiting NCT00001160 - Studies on Tumors of the Thyroid
Completed NCT05052359 - Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
Terminated NCT03630120 - Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Phase 2
Recruiting NCT04948437 - Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
Recruiting NCT05463107 - Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
Completed NCT01100619 - A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Phase 1
Completed NCT00668811 - Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Phase 2